Rob van der Laarse

Review of clinical brachytherapy uncertainties: Analysis guidelines of GEC-ESTRO and the AAPM

Background and purpose A substantial reduction of uncertainties in clinical brachytherapy should result in improved outcome in terms of increased local control and reduced side effects. Types of uncertainties have to be identified, grouped, and quantified. Methods A detailed literature review was performed to identify uncertainty components and their relative importance to the combined overall uncertainty. Results Very few components (e.g., source strength and afterloader timer) are independent of clinical disease site and location of administered dose. While the influence of medium on dose calculation can be substantial for low energy sources or non-deeply seated implants, the influence of medium is of minor importance for high-energy sources in the pelvic region. The level of uncertainties due to target, organ, applicator, and/or source movement in relation to the geometry assumed for treatment planning is highly dependent on fractionation and the level of image guided adaptive treatment. Most studies to date report the results in a manner that allows no direct reproduction and further comparison with other studies. Often, no distinction is made between variations, uncertainties, and errors or mistakes. The literature review facilitated the drafting of recommendations for uniform uncertainty reporting in clinical BT, which are also provided. The recommended comprehensive uncertainty investigations are key to obtain a general impression of uncertainties, and may help to identify elements of the brachytherapy treatment process that need improvement in terms of diminishing their dosimetric uncertainties. It is recommended to present data on the analyzed parameters (distance shifts, volume changes, source or applicator position, etc.), and also their influence on absorbed dose for clinically-relevant dose parameters (e.g., target parameters such as D90 or OAR doses). Publications on brachytherapy should include a statement of total dose uncertainty for the entire treatment course, taking into account the fractionation schedule and level of image guidance for adaptation. Conclusions This report on brachytherapy clinical uncertainties represents a working project developed by the Brachytherapy Physics Quality Assurances System (BRAPHYQS) subcommittee to the Physics Committee within GEC-ESTRO. Further, this report has been reviewed and approved by the American Association of Physicists in Medicine.

Effect of electron contamination on scatter correction factors for photon beam dosimetry

Physical quantities for use in megavoltage photon beam dose calculations which are defined at the depth of maximum absorbed dose are sensitive to electron contamination and are difficult to measure and to calculate. Recently, formalisms have therefore been presented to assess the dose using collimator and phantom scatter correction factors, Sc and Sp, defined at a reference depth of 10 cm. The data can be obtained from measurements at that depth in a miniphantom and in a full scatter phantom. Equations are presented that show the relation between these quantities and corresponding quantities obtained from measurements at the depth of the dose maximum. It is shown that conversion of Sc and Sp determined at a 10 cm depth to quantities defined at the dose maximum such as (normalized) peak scatter factor, (normalized) tissue-air ratio, and vice versa is not possible without quantitative knowledge of the electron contamination. The difference in Sc at dmax resulting from this electron contamination compared with Sc values obtained at a depth of 10 cm in a miniphantom has been determined as a multiplication factor, Scel, for a number of photon beams of different accelerator types. It is shown that Scel may vary up to 5%. Because in the new formalisms output factors are defined at a reference depth of 10 cm, they do not require Scel data. The use of Sc and Sp values, defined at a 10 cm depth, combined with relative depth-dose data or tissue-phantom ratios is therefore recommended. For a transition period the use of the equations provided in this article and Scel data might be required, for instance, if treatment planning systems apply Sc data normalized at d(max).

A comparison of inverse optimization algorithms for HDR/PDR prostate brachytherapy treatment planning

PURPOSE Graphical optimization (GrO) is a common method for high-dose-rate/pulsed-dose-rate (PDR) prostate brachytherapy treatment planning. New methods performing inverse optimization of the dose distribution have been developed over the past years. The purpose is to compare GrO and two established inverse methods, inverse planning simulated annealing (IPSA) and hybrid inverse treatment planning and optimization (HIPO), and one new method, enhanced geometric optimization-interactive inverse planning (EGO-IIP), in terms of speed and dose-volume histogram (DVH) parameters. METHODS AND MATERIALS For 26 prostate cancer patients treated with a PDR brachytherapy boost, an experienced treatment planner optimized the dose distributions using four different methods: GrO, IPSA, HIPO, and EGO-IIP. Relevant DVH parameters (prostate-V100%, D90%, V150%; urethra-D(0.1cm3) and D(1.0cm3); rectum-D(0.1cm3) and D(2.0cm3); bladder-D(2.0cm3)) were evaluated and their compliance to the constraints. Treatment planning time was also recorded. RESULTS All inverse methods resulted in shorter planning time (mean, 4-6.7 min), as compared with GrO (mean, 7.6 min). In terms of DVH parameters, none of the inverse methods outperformed the others. However, all inverse methods improved on compliance to the planning constraints as compared with GrO. On average, EGO-IIP and GrO resulted in highest D90%, and the IPSA plans resulted in lowest bladder D2.0cm3 and urethra D(1.0cm3). CONCLUSIONS Inverse planning methods decrease planning time as compared with GrO for PDR/high-dose-rate prostate brachytherapy. DVH parameters are comparable for all methods.

Improved tumour control probability with MRI-based prostate brachytherapy treatment planning

Abstract Backgroun. Due to improved visibility on MRI, contouring of the prostate is improved compared to CT. The aim of this study was to quantify the benefits of using MRI for treatment planning as compared to CT-based planning for temporary implant prostate brachytherapy. Material and methods. CT and MRI image data of 13 patients were used to delineate the prostate and organs at risk (OARs) and to reconstruct the implanted catheters (typically 12). An experienced treatment planner created plans on the CT-based structure sets (CT-plan) and on the MRI-based structure sets (MRI-plan). Then, active dwell-positions and weights of the CT-plans were transferred to the MRI-based structure sets (CT-planMRI-contours) and resulting dosimetric parameters and tumour control probabilities (TCPs) were studied. Results. For the CT-planMRI-contours a statistically significant lower target coverage was detected: mean V100 was 95.1% as opposed to 98.3% for the original plans (p < 0.01). Planning on CT caused cold-spots that influence the TCP. MRI-based planning improved the TCPs by 6–10%, depending on the parameters of the radiobiological model used for TCP calculation. Basing the treatment plan on either CT- or MRI-delineations does not influence plan quality. Conclusion. Evaluation of CT-based treatment planning by transferring the plan to MRI reveals underdosage of the prostate, especially at the base side. Planning on MRI can prevent cold-spots in the tumour and improves the TCP.

Deviations from the planned dose during 48 hours of stepping source prostate brachytherapy caused by anatomical variations

BACKGROUND AND PURPOSE To determine the uncertainties in planned dose associated with catheter and organ movement during 48 hours of stepping source prostate brachytherapy. MATERIAL AND METHODS Pulsed-dose rate (PDR) prostate brachytherapy as a boost is given in 24 pulses every 2 hours, making the total treatment last 48 hours. The entire treatment is based on one plan, created on the planning CT (CT1). Two follow-up CTs (CT2 and CT3) were acquired; halfway through the treatment and at the end of treatment. On these repeat scans the catheters were reconstructed and PTV and OARs were delineated. The original treatment plan was calculated on the repeat CTs. Target coverage V(100%), D(90), dose to 2cm(3) (D2cm(3)) of the rectum and bladder and dose to 0.1cm(3) of the urethra were recorded from the recalculated DVHs. RESULTS On the two repeat CTs the V100% decreased -1.5% and -2.3% as compared to the planning CT. For the rectum D2cm(3), the average increase was 14.8% (CT1-CT2) and 17.3% (CT1-CT3). Increase in bladder D2cm(3) was on average 23.1% (CT1-CT2) and 24.8% (CT1-CT3). For the urethra D0.1cm(3) an average decrease of -2% (CT1-CT2) and -3.2% (CT2-CT3) was observed. CONCLUSIONS Changes in target coverage during treatment were small and considered clinically irrelevant. However, an overall increase in dose to the OARs was found as compared to the planned dose, which should be taken into account during treatment planning.

Novel tools for stepping source brachytherapy treatment planning: Enhanced geometrical optimization and interactive inverse planning

PURPOSE Dose optimization for stepping source brachytherapy can nowadays be performed using automated inverse algorithms. Although much quicker than graphical optimization, an experienced treatment planner is required for both methods. With automated inverse algorithms, the procedure to achieve the desired dose distribution is often based on trial-and-error. METHODS A new approach for stepping source prostate brachytherapy treatment planning was developed as a quick and user-friendly alternative. This approach consists of the combined use of two novel tools: Enhanced geometrical optimization (EGO) and interactive inverse planning (IIP). EGO is an extended version of the common geometrical optimization method and is applied to create a dose distribution as homogeneous as possible. With the second tool, IIP, this dose distribution is tailored to a specific patient anatomy by interactively changing the highest and lowest dose on the contours. RESULTS The combined use of EGO-IIP was evaluated on 24 prostate cancer patients, by having an inexperienced user create treatment plans, compliant to clinical dose objectives. This user was able to create dose plans of 24 patients in an average time of 4.4 min/patient. An experienced treatment planner without extensive training in EGO-IIP also created 24 plans. The resulting dose-volume histogram parameters were comparable to the clinical plans and showed high conformance to clinical standards. CONCLUSIONS Even for an inexperienced user, treatment planning with EGO-IIP for stepping source prostate brachytherapy is feasible as an alternative to current optimization algorithms, offering speed, simplicity for the user, and local control of the dose levels.

Comparison of parameterization methods of the collimator scatter correction factor for open rectangular fields of 6-25 MV photon beams

Abstract Purpose : To facilitate the use of the collimator scatter correction factor, S c , parametrization methods that relate S c to the field size by fitting were investigated. Materials and methods : S c was measured with a mini-phantom for five types of dual photon energy accelerators with energies varying between 6 and 25 MV. Using these S c -data six methods of parametrizing S c for square fields were compared, including a third-order polynomial of the natural logarithm of the field size normalized to the field size of 10 cm 2 . Also five methods of determining S c for rectangular fields were considered, including one which determines the equivalent field size by extending Sterlings method. Results : The deviations between measured and calculated S c -values were determined for all photon beams and methods investigated in this study. The resulting deviations of the most accurate method varied between 0.07 and 0.42% for square fields and between 0.26 and 0.79% for rectangular fields. A recommendation is given as to how to limit the number of fields for which S c should be measured in order to be able to accurately predict it for an arbitrary field size.

Exploring trade-offs between target coverage, healthy tissue sparing, and the placement of catheters in HDR brachytherapy for prostate cancer using a novel multi-objective model-based mixed-integer evolutionary algorithm

Brachytherapy is a form of radiotherapy whereby a radiation source is guided near tumors, using devices such as catheter implants. In the present clinical workflow, catheters are first placed inside or close to the tumor based on clinical expertise. Subsequently, software is used to design a plan for the delivery of radiation. Treatment planning is essentially a multi-objective optimization problem, where conflicting objectives represent radiation delivered to tumor cells and healthy cells. However, current clinical software collapses this information into a single-objective, constrained optimization problem. Moreover, catheter positioning is typically not included. As a consequence, it is hard to obtain insight into the true nature of the trade-offs between key planning objectives and the placement of catheters. Such insights are however crucial in understanding how better treatment plans may be constructed. To obtain such insights, we interface with real-world clinical software and derive potential catheter positions for real-world patients. Selecting and configuring catheters requires mixed-integer optimization. For this reason, we extend the recently-proposed Genetic Algorithm for Model-Based mixed-Integer opTimization (GAMBIT) to tackle multi-objective optimization problems. Our results indicate that clinically acceptable plans of high quality may be achievable with less catheters than typically used in current clinical practice.